Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terrance D Barrett

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Biochemical and Biophysical Research Communications|April 10, 2007
Obestatin reduces food intake and suppresses body weight gain in rodentsGuy J Lagaud, Andy Young, Auzon Acena, et al.
Bioorganic & Medicinal Chemistry Letters|October 21, 2005
Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivityClark Sehon, Kelly McClure, Michael Hack, et al.
Bioorganic & Medicinal Chemistry Letters|October 21, 2005
Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivityKelly McClure, Michael Hack, Liming Huang, et al.
Hematology (Amsterdam, Netherlands)|March 6, 2020
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunctionJoi Ninomoto, Ahmad Mokatrin, Taisei Kinoshita, et al.
Advances in Therapy|January 23, 2023
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisTomas Ganz, Elizabeta Nemeth, Stefano Rivella, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonistsLaurent Gomez, Michael D Hack, Kelly McClure, et al.
The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.
ACS Omega|June 11, 2019
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2Scott D Bembenek, Hariharan Venkatesan, Hillary M Peltier, et al.
Circulation|March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS ProgramKarin Rådholm, Gemma Figtree, Vlado Perkovic, et al.
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Biochemical and Biophysical Research Communications|April 10, 2007
Obestatin reduces food intake and suppresses body weight gain in rodentsGuy J Lagaud, Andy Young, Auzon Acena, et al.
Bioorganic & Medicinal Chemistry Letters|October 21, 2005
Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivityClark Sehon, Kelly McClure, Michael Hack, et al.
Bioorganic & Medicinal Chemistry Letters|October 21, 2005
Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivityKelly McClure, Michael Hack, Liming Huang, et al.
Hematology (Amsterdam, Netherlands)|March 6, 2020
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunctionJoi Ninomoto, Ahmad Mokatrin, Taisei Kinoshita, et al.
Advances in Therapy|January 23, 2023
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisTomas Ganz, Elizabeta Nemeth, Stefano Rivella, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonistsLaurent Gomez, Michael D Hack, Kelly McClure, et al.
The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.
ACS Omega|June 11, 2019
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2Scott D Bembenek, Hariharan Venkatesan, Hillary M Peltier, et al.
Circulation|March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS ProgramKarin Rådholm, Gemma Figtree, Vlado Perkovic, et al.
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Pageof 4